Changes to This Summary (06/07/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added National Comprehensive Cancer Network (NCCN) as reference 77.
Added NCCN as reference 84.
Added text to state that data from the Cancer Family Registry suggest that breast cancer and prostate cancer may also be considered in the spectrum of Lynch syndrome (LS)-associated tumors.
Added text about the overlap in symptoms between juvenile polyposis syndrome and hereditary hemorrhagic telangiectasia; the prevalence of germline mutations in ALK1, ENG, and SMAD4; and considerations for surveillance and genetic testing in these patients (cited 2004 Gallione et al., 2006 Gallione et al., Aretz et al., and O'Malley et al. as references 425, 426, 427, and 428, respectively).
Added text about a quality-of-life and functional outcome survey of LS patients in which global quality-of-life outcomes were comparable among patients with more extensive and less extensive resections (cited Haanstra et al. as reference 81).
The Risk-reducing surgery for familial adenomatous polyposis subsection was extensively revised.
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.